Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, Follicular × ofatumumab × Clear all

Phase

Phase 2 7 Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6 Neoplasms 3 Leukemia, B-Cell 3 Recurrence 2 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma 1 Leukemia 1 Bronchiolitis Obliterans Syndrome 1 Autoimmune Diseases of the Nervous System 1 Anti-N-Methyl-D-Aspartate Receptor Encephalitis 1

Interventions

Rituximab 59 Cyclophosphamide 36 Vincristine 30 Prednisone 29 Doxorubicin 24 Lenalidomide 16 Radiotherapy 15 Bendamustine Hydrochloride 13 Etoposide 9 Peripheral Blood Stem Cell Transplantation 8 Filgrastim 8 tofacitinib 7 Prednisolone 7 obinutuzumab 6 VAP-cyclo protocol 6 Deoxycholic Acid 6 ibritumomab tiuxetan 5 fludarabine 5 Mitoxantrone 5 Methylprednisolone 5 Cytarabine 5 ibrutinib 4 fludarabine phosphate 4 R-CHOP protocol 4 Melphalan 4 Dexamethasone 4 Carmustine 4 tositumomab I-131 3 Radiation 3 Methotrexate 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01077518 2020-03-27

A+B

Novartis

Phase 3 Terminated

346 enrolled 41 charts

Lymphoma, Follicular, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡